ublituximab
tg therapeutics
['ublituximab', '$tgtx']
 ublituximab, a novel, glycoengineered anti-cd20 monoclonal antibody (mab), demonstrates enhanced antibody-dependent cellular cytolysis (adcc) relative to other anti-cd20 mabs #aanam2023 $tgtx #aanam 
No investment advice. Do your own DD Market is all about taking the shares from the weak holders& providing opportunities to those that have the stamina to hold